BioSpace News Archive

Oyster Point Pharma, Inc. (Nasdaq: OYST), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies to treat ocular surface diseases, today announced the expansion of its pipeline with the introduction of Enriched Tear Film (ETF™) Gene Therapy and proof-of-concept in vivo study results from its first gene therapy candidate, OC-101.

Rain Therapeutics Inc., a clinical-stage company developing precision oncology therapeutics, today announced a master program and a genomic analysis platform agreement for comprehensive genomic profiling tests utilizing artificial intelligence and precision medicine company Tempus’ genomic analysis platform.

Summit Therapeutics Inc. invites our shareholders and other interested parties to attend our Company’s Annual Shareholders’ Meeting, which will be held virtually on Wednesday, June 16, 2021, at 1:00 pm Eastern Time.

Kintara Therapeutics, Inc. (Nasdaq: KTRA) (“Kintara” or the “Company”), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it has enrolled the final patient in the adjuvant arm of its ongoing Phase 2 clinical study of VAL-083 being conducted at the MD Anderson Cancer Center (MD Anderson)

Unchained Labs, the life science tools company that’s all about getting biologics and gene therapy researchers the right tools for the job, announced the additions of Tom O’Lenic as Chief Commercial Officer and Don Phelps as VP Finance.

Imago BioSciences, Inc. (“Imago”), a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs), today announced the appointment of Wan-Jen Hong, M.D., as chief medical officer.

Walgreens Boots Alliance, Inc. will release its fiscal 2021 third quarter earnings results at 7 a.m. Eastern time Thursday, July 1, 2021 followed by a one-hour conference call with WBA management beginning at 8:30 a.m. Eastern time.

Guangzhou Bio-Gene, a clinical-stage biopharmaceutical company developing a pipeline of innovative oncology therapies, today announced the company will present at the 2021 American Society of Clinical Oncology (“ASCO”) Annual Meeting taking place June 4-8 th , 2021.

RNA Disease Diagnostics, Inc. (RNADD), a company developing a best-in-class molecular diagnostics platform for infectious disease detection, announced today that the U.S. Food and Drug Administration (FDA) has registered the laboratory of Dipanjan Pan, MSc, PhD at the University of Maryland School of Medicine (UMSOM), as an approved laboratory development site for RNADD’s Antisense COVID-19 molecular diagnostic test.

Studies published in two journals, International Journal of Periodontics & Restorative Dentistry and Lasers in Medical Science, support use of proprietary Er,Cr:YSGG laser technology for peri-implantitis treatments